Tag:
Advair
Latest Headlines
Latest Headlines
Prosonix: Scrap excipients for better respiratory delivery
Prosonix says its new platform for multi-API powders could be the way to boost effectiveness for inhaled treatments.
Novartis touts positive results for COPD inhalant
Novartis is reporting positive results from Phase III trials of QVA149, a COPD drug that uses the company's Breezhaler dry powder inhaler for delivery
GlaxoSmithKline undeterred by spotty results for Relovair
GlaxoSmithKline ( $GSK ) is pushing ahead with its plan to submit Relovair to regulators for approval this year.
Forest Labs notches victory en route to FDA ruling on COPD drug
Eyeing the major market for a chronic lung condition, Forest Laboratories ( $FRX ) picked up the backing of an FDA panel for its experimental COPD drug known as aclidinium. It's a key endorsement...
Theravance shares tank on troubling study results for Relovair
by Suzanne Elvidge and John Carroll Shares of GlaxoSmithKline ( $GSK ) caught a chill this morning after investigators released mixed late-stage data and flagged troubling safety concerns for its COPD
New year brings new delay for SkyePharma's Flutiform asthma inhaler
It's likely that SkyePharma isn't having a "Happy New Year" just yet. That's because the British drug delivery company now stands to face an additional delay of between 6 and 9 months in the approval
Mylan snags Pfizer's Advair copy, inhaler technology
Look out, GlaxoSmithKline ( $GSK ). Mylan ( $MYL ) has snapped up some drug delivery technology from Pfizer ( $PFE ), aiming to knock off GSK's blockbuster respiratory drugs Advair Diskus and Seretide
Lipitor's $131B lifetime sales dwarf other megablockbusters
The names of the five best-selling drugs of all time aren't much of a surprise: Lipitor, Plavix, Zocor, Seretide/Advair, and Nexium. But what might be surprising are the figures attached. Pfizer's
Dutch study pits GSK's Diskus against Elpenhaler
Some Dutch researchers wanted to know how a new generic version of GlaxoSmithKline's ( $GSK ) asthma drug Advair matches up against the real thing. The issue is whether the Greek generics maker's
GSK sales grow, thanks to emerging markets, Japan
Color GlaxoSmithKline ( $GSK ) happy. The U.K. drugmaker posted sales growth of 4% for the third quarter, beating analyst estimates. But the really good news is the company's outlook for next year. GSK
